Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

Inclusion Criteria: * Scleroderma (SSc) participants: * Diagnosed with SSc as defined by the American College of Rheumatology within the past 5 years AND fulfill criteria for diffuse cutaneous SSc according to LeRoy classification * Diagnosed with SSc as defined by the American College of Rheumatology within the past 3 years AND have documented evidence of RNA Polymerase III or anti-topoisomerase antibody positivity * Healthy controls must be free of SSc or other autoimmune disease and have no known skin pathology Exclusion Criteria: * Diagnosis of skin malignancy within the previous 2 years, excluding adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ. * Presence of wounds or skin rashes at the site of Spatial frequency domain imaging (SFDI) measurement or skin biopsy * Presence of other co-morbid illnesses with an estimated median life expectancy \< 5 years. Exclusion criteria for providing a skin biopsy sample during the study but are not exclusions for enrollment in the study. * Subject has known allergy to lidocaine or has had a reaction to local anesthetics in the past will not provide skin biopsy samples at any time during the study. * Subjects who, in the opinion of the investigator, are high-risk for small tissue calcification, or other conditions that may affect wound healing will not provide skin biopsy samples at any time during the study. * Subjects who are pregnant or lactating are excluded from providing a skin biopsy sample only while they are pregnant or lactating.